A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development
Contemporary Clinical Trials · 2023
DOI: 10.1016/j.cct.2023.107119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2023. Verfasst von Pingye Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Statistics and Data Science, BeiGene, Ltd., Ridgefield Park, NJ, USA. Electronic address: pingyezhangusc@gmail.com. Hauptthemen laut MEDLINE: Research Design, Medical Oncology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
In a recent article, Zhang et al. proposed a 2-in-1 adaptive design to seamlessly expand a selected dose, based on efficacy compared to the control arm, from a Phase 2 trial to a Phase 3 trial for oncology drug development. In this article, we communicate a variation of the proposed design which selects a dose to expand based on direct comparison of high dose to low dose when both doses demonstrate promising efficacy compared to the control arm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Statistics and Data Science, BeiGene, Ltd., Ridgefield Park, NJ, USA. Electronic address: pingyezhangusc@gmail.com.
- Global Statistics and Data Science, BeiGene, Ltd., Ridgefield Park, NJ, USA.
- Department of Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA.
Zitieren
APA
Zhang, P., Li, X. N., Lu, K., Wu, C., & Ge, M. (2023). A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2023.107119
Vancouver
Zhang P, Li XN, Lu K, Wu C, Ge M. A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development. Contemporary Clinical Trials. 2023. doi:10.1016/j.cct.2023.107119
BibTeX
@article{Zhang2023,
author = {Zhang, Pingye and Li, Xiaoyun Nicole and Lu, Kaifeng and Wu, Chengqing and Ge, Miaomiao},
title = {A variation of a 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development},
journal = {Contemporary Clinical Trials},
year = {2023},
doi = {10.1016/j.cct.2023.107119}
}
EUVIMED